Israel to offer AstraZeneca's Evusheld to immunocompromised people
JERUSALEM, Feb 15 (Reuters) - Israel will start offering AstraZeneca's (AZN.L) antibody cocktail Evusheld, which is used to prevent COVID-19, to people with compromised immune systems who did not get a sufficient antibody boost from vaccines.
Evusheld has been approved by the U.S. Food and Drug Administration and has proven to be 83% effective in preventing serious illness and death from COVID-19, the Health Ministry said on Tuesday.
It is not a treatment for those already sick or a prevention for those already exposed to the virus, it said.
Evusheld will be made available for people 12 and older who weigh more than 40 kg (88 lb), according to a Health Ministry statement.
It said Evusheld will "be given regardless of past recovery from COVID-19 or receiving previous coronavirus vaccine doses, provided that two weeks have passed since getting the vaccine."
Our Standards: The Thomson Reuters Trust Principles.